Vabysmo™ (faricimab-svoa intravitreal)

Vabysmo (faricimab‑svoa) is covered only for the FDA‑approved indications—neovascular (wet) AMD, diabetic macular edema, and macular edema following retinal vein occlusion—for up to 12 months; non‑FDA uses are not covered. Coverage requires administration by or under the supervision of an ophthalmologist, documentation of the FDA‑approved diagnosis and dosing records, and adherence to dosing limits (6 mg intravitreal: for nAMD up to every 4 weeks for four initial doses then no more often than every 8 weeks; for DME/RVO no more often than every 4 weeks).

"Neovascular (wet) age-related macular degeneration (nAMD)"

Sign up to see full coverage criteria, indications, and limitations.